OncoMatch/Clinical Trials/NCT06498752
MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer
Is NCT06498752 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies PD-1 monoclonal antibody consolidation therapy for esophageal cancer.
Treatment: PD-1 monoclonal antibody consolidation therapy — To further validate the performance of the high-sensitivity MRD assay in patients with squamous esophageal cancer who have completed radical radiotherapy; to validate whether MRD-negative patients can maintain a good prognosis under regular follow-up; and to validate whether MRD-positive patients can improve their survival with consolidation therapy with PD-1 monotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage I, II, III, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: radiation therapy — definitive/radical
Completed radical radiotherapy (dose 50-60Gy)
Must have received: platinum-based chemotherapy — systemic
Received a systemic regimen of platinum in combination with paclitaxel
Must have received: taxane (paclitaxel) — systemic
platinum in combination with paclitaxel
Must have received: antimetabolite (5-FU) — systemic
5-FU-based two-drug regimen
Must have received: antimetabolite (S-1) — systemic
S-1 monotherapy in elderly patients
Cannot have received: systemic therapy (chemotherapy alone or chemotherapy combined with immunotherapy)
Received systemic therapy (chemotherapy alone or chemotherapy combined with immunotherapy) for more than 4 cycles
Lab requirements
Blood counts
no significant abnormality
Kidney function
no significant abnormality
Liver function
no significant abnormality
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify